Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1464110 | 0.97 | CA2 (0.51) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL12175416 | 0.91 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL27292255 | 0.89 | CA2 (0.48) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL470113 | 0.87 | CA2 (0.54) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL15418237 | 0.86 | SMN1; SMN2 (0.56) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL15418182 | 0.83 | ALDH1A1 (0.58) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3280990 | 0.83 | CA2 (0.36) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL15928442 | 0.82 | SMN1; SMN2 (0.59) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL9972151 | 0.82 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL13248148 | 0.82 | CA2 (0.49) | CA2TSHRSMN1; SMN2ALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339983-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | UNIVERSITY OF MASSACHUSETTS | 2020-10-29 | — | — | US | disclosed |
| US-20190185855-A1 | CONJUGATED OLIGONUCLEOTIDES | UNIVERSITY OF MASSACHUSETTS | 2019-06-20 | — | — | US | disclosed |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | UNIVERSITY OF MASSACHUSETTS | 2017-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339983-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | DCLRE1B, RTCB, RNASE1 | CA2 4421/4885TSHR 2127/4885SMN1; SMN2 301/4885 |
| US-20170043024-A1 | BIOACTIVE CONJUGATES FOR OLIGONUCLEOTIDE DELIVERY | DCLRE1B, RTCB, RNASE1 | CA2 4421/4885TSHR 2127/4885SMN1; SMN2 301/4885 |
| US-20190185855-A1 | CONJUGATED OLIGONUCLEOTIDES | DCLRE1B, DCLRE1A, TNNC1 | CA2 4428/4885TSHR 1065/4885SMN1; SMN2 127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.